While Autolus Therapeutics plc ADR has underperformed by -0.08%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AUTL rose by 196.65%, with highs and lows ranging from $7.45 to $1.61, whereas the simple moving average jumped by 53.45% in the last 200 days.
On November 09, 2023, Deutsche Bank started tracking Autolus Therapeutics plc ADR (NASDAQ: AUTL) recommending Buy. Bryan Garnier also rated AUTL shares as ‘Buy’, setting a target price of $5 on the company’s shares in an initiating report dated March 17, 2023. Jefferies June 14, 2021d the rating to Buy on June 14, 2021, and set its price target from $6 to $12. JP Morgan January 29, 2021d its ‘Overweight’ rating to ‘Neutral’ for AUTL, as published in its report on January 29, 2021. H.C. Wainwright’s report from December 28, 2020 suggests a price prediction of $19 for AUTL shares, giving the stock a ‘Buy’ rating. JP Morgan also rated the stock as ‘Overweight’.
Analysis of Autolus Therapeutics plc ADR (AUTL)
Further, the quarter-over-quarter decrease in sales is -100.00%, showing a negative trend in the upcoming months.
To gain a thorough understanding of Autolus Therapeutics plc ADR’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -101.61% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 8.16, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and AUTL is recording an average volume of 1.75M. On a monthly basis, the volatility of the stock is set at 6.85%, whereas on a weekly basis, it is put at 7.66%, with a gain of 15.03% over the past seven days. Furthermore, long-term investors anticipate a median target price of $10.29, showing growth from the present price of $6.20, which can serve as yet another indication of whether AUTL is worth investing in or should be passed over.
How Do You Analyze Autolus Therapeutics plc ADR Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 15.01%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 60.96% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
AUTL shares are owned by institutional investors to the tune of 60.96% at present.
